 Immunome Inc NASDAQ: IMNM has secured additional funding of 4.3 million from the Department of Defense DoD for the development of an antibody cocktail IMM-BCP-01 to combat SARS-CoV-2 and its variants. The additional capital comes less than a year after an initial DOD award of 13.3 million, bringing the total commitment to Immunome to 17.6 million. 